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Background: Preoperative pain, type of operation and anesthesia, severity of acute postoperative pain, and
psychosocial factors have been identified as risk factors for chronic postsurgical pain (CPP). Recently, it has been
suggested that genetic factors also contribute to CPP. In this study, we aimed to determine whether the catechol-
O-methyl transferase (COMT) and opioid receptor μ-1 (OPRM1) common functional polymorphisms rs4680 and
rs1799971 were associated with the incidence, intensity, or duration of CPP in patients after lower abdominal
surgery.
Methods: One hundred and two patients with American Society of Anesthesiologists (ASA) physical status I/II
underwent either abdominal radical prostatectomy (n = 45) or hysterectomy (n = 57). The incidences of CPP in the
pelvic and scar areas were evaluated in all patients three months after surgery.
Results: Thirty-five (34.3%) patients experienced CPP after lower abdominal surgery. Within this group, six (17.1%)
patients demonstrated symptoms of neuropathic pain. For COMT rs4680, 22 (21.6%) patients had Met158Met, 55
(53.9%) patients had Val158Met, and 25 (24.5%) patients had Val158Val. No association was found between CPP
phenotypes (incidence, intensity, and duration) and different rs4680 genotypes. For OPRM1 rs1799971, only CPP
patients carrying at least one copy of the G allele had higher pain intensity than A118A carriers (p=0.02). No
associations with other phenotypes were found. No combined effect of COMT/OPRM1 polymorphisms on CPP
phenotypes was observed.
Conclusions: OPRM1 genotype influences CPP following lower abdominal surgery. COMT didn’t affect CPP,
suggesting its potential modality-specific effects on human pain.
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Chronic postsurgical pain (CPP) varies between type of
operation and between patient populations, but it is
clearly a common complication after surgery [1]. Surgery
itself or tissue damage pose a significant risk for chronic
or long-lasting pain; however, the variability in this pain
cannot be explained only by surgery- or treatment-related
factors [2]. Thus, the identification of other risk factors for
CPP is important for the prediction of patients at risk and
development of strategies to prevent CPP. Pre-operative* Correspondence: belferi@upmc.edu
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severity, and psychosocial characteristics have been identi-
fied as risk factors for this complication [1,3]. Recently, it
has been suggested that genetic factors also contribute to
CPP [4,5]. Several genetic polymorphisms were found to
be associated with different types of chronic pain, such as
in the GTP cyclohydrolase enzyme (GCH1) [6], potassium
channel subunit (KCNS1) [7], and catechol-O-methyl
transferase (COMT) [8] genes, which play a role in per-
sistent radiculapathic pain following surgical discectomy
[6,7], postamputation pain [7], and chronic orafacial
pain [8], respectively. COMT contains the well-known
common functional single nucleotide polymorphism
(SNP) rs4680, or G1947A, encoding for Val158Mettral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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associated with a three- to four-fold reduction of COMT
enzyme activity, compared to homozygosity for the
158Val variant, resulting in reduced degradation of syn-
aptic catecholamines [9]. Zubieta and colleagues found
that COMT Val158Met polymorphism contributed to
pain phenotypes via μ-opioid-related mechanisms [10].
Homozygosity for the 158Met allele was associated with
diminished regional μ-opioid system responses to pain
and increased μ-opioid receptor binding potential [10].
Thus, an increase in the density of μ-opioid receptors
possessing a homozygous Met158Met genotype may
result in the improved efficacy of morphine as well as
endogenous opioids during stress. The gene encoding
opioid receptor μ-1 (OPRM1) also has a well-established
functional SNP rs1799971, or A118G, that contributes to
human pain [11]. Recently, we published a study where we
investigated the joint effect of COMT and OPRM1 poly-
morphisms on the morphine response in postoperative
analgesia [12]. We found that in patients undergoing
lower abdominal surgery, the first 48 hours of morphine
consumption and acute pain relief varied according to
genotype. Joint carriers of OPRM1, A118G, and COMT
Val158Met required a morphine dosage 18% less than that
of OPRM1, A118A, and COMT Val158Val carriers [12].
In the present study, we used the same patient population
to determine whether COMT and OPRM1 polymorphisms
contribute to chronic pain after lower abdominal surgery.
Results
We studied 102 patients 34.3% (n = 35) who experienced
postsurgical pain in the pelvic and scar regions three
months after lower abdominal surgery. The average inten-
sity of pain was 3.7±1.5 (pain score on a Numeric Rating
Scale [NRS]), and the average duration was 10.3±12.0 days.
Within this group, six patients (17.1%) demonstrated
symptoms of neuropathic-like pain at pain clinic examin-
ation. Twenty of 35 CPP patients used pain medications
including diclofenac, paracetamol, and/or ibuprofen to
alleviate pain.
We found no statistically significant difference in patient
demographics between the CPP and non-CPP groups: the
mean ages of each group were 53.9±9.8 and 54.8±10.6,
respectively (p=0.65). The gender distributions (40.0%
male vs. 46.3% female) were also similar (p=0.55). ThereTable 1 Summary of information for COMT rs4680 or OPRM1
Allelesa
SNP Chr Position A1 A2
rs4680 22 19951271 A (Met) G (Val)
rs1799971 6 154402490 G A
a: A1: Minor or Variant allele; A2: Major or wild-type allele.
b: MAF: Minor allelic frequency.
c: Hardy-Weinberg Equilibrium (HWE) test P-value.were no significant differences in intensity of acute pain or
morphine consumption in the early postoperative period
(first 48 hours) between patients with CPP and patients
without it (p = 0.13). Furthermore, we found no statistical
differences in the intensity of acute pain and CPP between
males and females (Additional file 1: Table S1) or in the
distribution patterns of either OPRM1, A118G, or COMT
G1947A SNP between males and females in all of the pa-
tients, the CPP patients, and the non-CPP patients,
respectively (Additional file 2: Table S2).
Table 1 displays allelic frequency data for COMT
rs4680 and OPRM1 rs1799971. For COMT rs4680,
22 (21.6%), 55 (53.9%), and 25 (24.5%) patients had
the A1947A (Met158Met), G1947A (Val158Met), and
G1947G (Val158Val) genotypes, respectively. For
OPRM1 rs1799971, 3 (2.9%), 15 (14.7%), and 84
(82.4%) patients had the G118G, A118G, and A118A
genotypes, respectively. Both SNPs were in Hardy-
Weinberg Equilibrium (Table 1).
Our analyses of the 102 patients did not show a signifi-
cant association between the two SNPs and the incidence
of CPP (rs4680, P = 0.74; rs1799971, P = 0.31) under the
additive genetic effect model after adjustment for baseline
pain score (postoperative acute pain in the post-anesthesia
care unit [PACU]), age, and gender. No significant
associations were identified assuming the dominant or
recessive genetic model of variant or minor allele of the
two SNPs (Table 2).
In the CPP group (35 patients), our analyses of
rs4680 did not identify any significant association with
the intensity of pain after adjusting for baseline acute
pain, age, and gender, assessing the additive (P = 0.30),
dominant (P = 0.27), and recessive (P = 0.57) genetic
models of the variant or minor allele (Table 3). There
was also no association of rs4680 with duration of pain
under the three genetic effect models. For rs1799971,
only one CPP patient had the G118G genotype; thus, the
recessive genetic model could not be assessed. We ob-
served a gene-dosage (worsening) effect of the rs1799971
variant allele G; that is, carriers of at least one copy of the
G allele had higher pain intensity scores than homozygous
A118A carriers (P = 0.02, adjusted for all covariates). No
statistical difference was found in duration of pain among
CPP patients with different genotypes of rs1799971
(Table 3).rs1799971
Genotype
MAFb A1/A1 A1/A2 A2/A2 HWEc
0.49 22 (21.6%) 55 (53.9%) 25 (24.5%) 0.55
0.10 3 (2.9%) 15 (14.7%) 84 (82.4%) 0.07
Table 2 Association of COMT rs4680 or OPRM1 rs1799971 genotypes with CPP incidence in 102 patients
SNP Genotypes CPP No CPP Total Padditive Pdominant Precessive
rs4680 Met158Met (AA) 10 12 22 (21.6%)
Val158Met (GA) 16 39 55 (53.9%)
Val158Val (GG) 9 16 25 (24.5%) 0.74 0.44 0.79
rs1799971 A118A 31 53 84 (82.4%)
A118G 3 12 15 (14.7%)
G118G 1 2 3 (2.9%) 0.31 0.22 0.95
Padditive, Pdominant, Precessive: P-value from logistic regression analysis of CPP status, assessing the additive, dominant and recessive genetic effect of rs4680 (or
rs1799971) after adjusting for baseline pain score, age and gender.
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COMT/OPRM1 genotypes: Val158Val (GG) /A118A
(21.6%), Met158Val (GA) /A118A (43.1%), Met158Met
(AA)/A118A (17.6%), and Met158Val (GA) /A118G (8.8%)
(Table 4). No significant associations of these genotypes
with the incidence of CPP were found (p = 0.46). However,
among the CPP patients, carriers (N = 2) of Met158Val
(GA) /A118G had higher pain intensity scores than car-
riers with the other three common combined genotypes
(p =0.005-0.029, Table 5). No significant differences in
pain duration were found among CPP patients with differ-
ent COMT/OPRM1 genotypes.
Discussion
Chronic postsurgical pain is a prevalent, though often
overlooked healthcare problem. Twenty-five percent of
patients attending pain clinics reported surgery as the
cause of chronic pain, with an estimated CPP incidence of
10-65% [13,14]. The incidence of chronic neuropathic pain
one year after surgery is between 0.5 and 1.5% [15,16].
Thirty-five (34.3%) patients in our study had residual per-
sistent pain three months after lower abdominal surgery,
and six patients had neuropathic pain syndrome. These
findings are consistent with previous studies that reported
pain incidences of up to 32% after lower abdominal sur-
gery in long-term follow up [14]. The mechanisms of CPP
are complex and not fully understood. Even for a single
surgical procedure, different pain syndromes have differ-
ent mechanisms of pathology [17]. One of the direct
causes of postoperative chronic pain is scar formation.
Scar tissue forms when the skin and tissue begin to heal,Table 3 Association of COMT rs4680 or OPRM1 rs1799971 gen
CPP patients
COMT rs4680 O
Val158Val
(GG; n = 10)
Val158Met
(GA; n= 17)
Met158Met
(AA; n = 8)
A118A (n = 31)
Pain Score 3.8 ± 1.2 4.0 ± 1.5 3.3 ± 1.7 3.5 ± 1.3
Duration 11.1 ± 10.5 11.7 ± 15.3 6.5 ± 2.3 10.3 ± 12.1
Data are expressed as mean ± SD.
P-value was from the ANCOVA of CPP score (or duration of pain) after adjusting for
dominant, and recessive genetic model of two SNPs. Recessive effect of G allele foroften leading to the pulling of surrounding tissues, com-
pression or irritation of nerve endings, and the entrap-
ment of nerve cells within the scar tissue itself [17,18]. In
addition, surgery can cause the release of inflammatory
mediators that activate primary afferent nociceptors, and
persistent pain can lead to peripheral sensitization. If
persistent pain ceases in the process of normal wound
healing, sensitization and facilitation of synaptic transmis-
sion to the central nervous system (CNS) is reversed and
normal nociceptor activity is restored [19,20]. The after-
effects of surgery, such as prolonged inflammation due
to the insertion of mesh materials or chronic nerve
stretching, can lead to sensitization and facilitation of syn-
aptic transmission that subsequently cause phenotypic
and pathophysiological changes in nociceptors [21]. These
include changes in gene expression, receptor translocation
to the cell membrane, sustained activation of glial cells,
and spinal facilitation of nociception. These structural
changes lead to pain amplification, later resulting in CPP
and discomfort around the surgical area [17].
Nonetheless, not all patients experience pain around the
scar area after surgery. Genetics, as well as interaction
between genetic and environmental factors, are likely to
influence inter-individual variability in CPP [5,9]. Namely,
functional genetic polymorphisms of the COMT gene are
associated with altered sensitivity to pain induced in an
experimental (controlled) environment. Low COMT ac-
tivity poses a high risk for the development of chronic
orafacial pain and fibromyalgia [22]. Decreased activity
of the COMT enzyme encoded by the 158Met allele
(variant allele of rs4680) may result in accumulation ofotypes with pain score or duration of pain (days) in 35
PRM1 rs1799971 P-value (COMT, OPRM1)
A118G (n = 3) G118G (n = 1) Additive Dominant Recessive
5.3 ± 2.3 6 0.30, 0.02 0.27, 0.02 0.57, NA
13.0 ± 14.9 3 0.44, 0.37 0.48, 0.60 0.57, NA
pain medication, age, sex, and baseline pain score, assessing additive,
rs179991 was not assessed as there was only patient with G118G.
Table 4 Association of combined COMT/OPRM1
genotypes with incidence of CPP in 102 patients
Combined COMT/OPRM1 genotypes CPP No CPP Total
Val158Val (GG)/A118A 10 12 22 (21.6%)
Met158Val (GA)/A118A 14 30 44 (43.1%)
Met158Met (AA)/A118A 7 11 18 (17.6%)
Met158Val (GA) /A118G 2 7 9 (8.8%)
Met158Met (AA) /A118G 1 3 4 (3.9%)
Met158Val (GA) /G118G 1 1 2 (2.0%)
Val158Val (GG) /A118G 0 2 2 (2.0%)
Val158Val (GG) /G118G 0 1 1 (1.0%)
Met158Met (AA) /A118G 0 0 0 (0%)
Total 35 67 102
Note: Association of common combined genotypes (freq > 5%, first four rows)
with the incidence of CPP was tested using a logistic regression analysis, after
adjusting for age, gender and baseline pain score (P-value = 0.46).
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CNS, leading to overstimulation of nociceptive beta
2/3-adrenergic pathways and high pain sensitivity as
observed in 118G carriers [23]. Furthermore, COMT
inhibition causes increased pain sensitivity comparable
to the pro-nociceptive effects of carrageenan mediated
by beta 2/3-adrenergic mechanisms [23]. Recently, we
showed the contribution of COMT functional variation
to clinical outcome after surgical treatment for disk de-
generative disease [24]. We also showed that cumulative
pain scores at rest recorded postoperatively in the same
cohort of surgery patients as used in this study were
lower in the first two postoperative days in the COMT
rs4680 Val/Val homozygous group compared to the
Met/Met homozygous group [12]. In this study, we
report no statistically significant association between
COMT rs4680 and the incidence, intensity, or duration
of CPP. These findings suggest the modality-specific
nature of COMT effects, e.g. it contributes to acute
postoperative pain after lower abdominal surgery, but
not persistently or chronically. These data are import-
ant, since COMT’s effects on human pain are still underTable 5 Association of combined COMT/OPRM1 genotypes wi
Co
Met158Val (GA)/A118G
(n = 2)
Val158Va
(n
Pain Score Adjusted mean
(95% CI)*
6.4 (4.6, 8.2) 3.4
Difference (95% CI),
P-value
Reference −3.0 (−5
Duration of
Pain
Adjusted mean
(95% CI)*
12.1 (−6.5, 30.7) 15.4
Difference (95% CI),
P-value
Reference 3.3 (−17
*: Adjusted least square means after adjusting for baseline pain, pain medication, sc
score, or duration of pain among Val158Val (GG)/A118A, Val158Val (GG)/A118A, andinvestigation, and more evidence is needed for a
complete picture. That COMT is not associated with
several pain conditions such as neuropathic pain syn-
dromes already points to possible modality-specific ef-
fects [25]; this study provides further evidence. Since
COMT genotyping may potentially have value for clin-
ical decision-making based on predicted pain severity or
time course or patients’ response to analgesia [26], it is
essential to further evaluate COMT’s effects in different
pain models and for multiple pain phenotypes to iden-
tify precisely the array of clinical settings in which
COMT could be used as a “pain biomarker”. Although
our results provide additional knowledge on the rela-
tionship between COMT and CPP, they are limited to
only one time point (three months postoperatively) and
should be confirmed in a larger clinical setting using
protocols specifically designed to investigate the inten-
sity, quality, and duration of pain in scar regions at dif-
ferent time points after surgery.
Functional genetic polymorphisms between altered pain
thresholds and analgesic responses to opioid administration
for the OPRM1 A118G genotype (rs1799971) have been
well characterized [11]. Previously, we evaluated these
alleles in an abdominal surgery patient cohort (this study
cohort) in relation to acute postoperative pain, opioid con-
sumption, and side effects. We found that patients with A
allele(s) had significantly less nausea scores compared to
the G118 homozygotes, but no association was observed
with pain itself [12]. In the current study, no association
was found between this OPRM1 SNP and the incidence of
CPP; however, the intensity of reported pain was signifi-
cantly higher in carriers of the G allele compared to the
homozygous AA carriers. Interestingly, these data match
results from several studies in other patient populations
where the G allele was found to be associated with ele-
vated mechanical pain responses, [12] as well as reduced
response to morphine and other opioids in patients
receiving treatment for postoperative or chronic pain
[27,28]. A larger-scale study is therefore needed to con-
firm that the OPRM1 G allele is a risk factor for chronicth pain score in CPP patients
mbined genotypes COMT/OPRM1
l (GG)/A118A
= 10)
Met158Val (GA)/A118A
(n = 14)
Met158Met (AA)/A118A
(n = 7)
(2.5, 4.2) 3.3 (2.6, 4.0) 4.0 (3.1, 5.0)
.1, -1.0), 0.005 −3.1 (−5.1, -1.0), 0.005 −2.4 (−4.5, -0.3), 0.029
(6.8, 24.0) 14.3 (7.0, 21.6) 10.3 (0.2, 20.4)
.2, 23.9), 0.74 2.2 (−18.7, 23.1), 0.83 −1.7 (−23.3, 19.8), 0.87
ore age, gender. No significant difference in either pain.
Val158Val (GG)/A118A.
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human pain models.
Although no significant association was found between
combined COMT/OPRM1 genotypes and the incidence
of chronic postsurgical pain in our study population, the
CPP patients with Met158Met/A118G had higher pain
scores than those patients with Val158Val/A118A,
Met158Val/A118A, and Met158Met/A118A. However, as
the sample size was too small to perform any powerful
analyses, the results need to be interpreted very cautiously
and more studies with larger sample sizes are needed to
validate this finding.
It is important to acknowledge a few limitations in our
study. Both genes tested have complex genetic structures,
and the two SNPs tested do not cover the diversity of
COMT and OPRM1 variation [5]. Although these SNPs
are the most studied and have proven functional conse-
quences, it is possible that other functional polymor-
phisms in these genes affect pain phenotypes related to
CPP. This study sample size didn’t allow us to assess other
functional but less common alleles. Furthermore, we had
limited statistical power to look for gene by gene inter-
action effects of CPP, and didn’t evaluate psychological
factors that may shape the effects of these genes.
Conclusion
No statistically significant association was found between
the incidence of CPP after lower abdominal surgery and
COMT/OPRM1 polymorphisms in this patient population.
Nevertheless, this data further improves our understand-
ing of the genetic background of different types of CPP,
and of the complexity of the effects of COMT and OPRM1
polymorphisms on human pain.
Methods
This study was approved by the local Human Studies
Committee in Tallinn, Estonia (No. 1356; 17.04.2008).
After providing informed consent, 102 Caucasian patients
with ASA physical status I/II (57 women and 45 men)
underwent abdominal surgery (for abdominal radical hys-
terectomy or prostatectomy, respectively [12]). Baseline
measures of arterial blood pressure, heart rate, respiratory
rate, and oxygen saturation were obtained by pulse oxim-
etry before initiation of anesthesia. Before anesthesia and
surgery, 5 mL of blood was collected from each patient
and stored for genetic analysis.
Intraoperative anesthesia
A standardized, general anesthesia technique was used
for all patients [12]. For induction of anesthesia, fentanyl
(2 mcg/kg), propofol (2 mg/kg), and atracurium (0.3 mg/
kg) were used. After induction, inhaled sevoflurane and
atracurium were chosen to maintain anesthesia. At the
end of the surgery, residual neuromuscular block wasantagonized with 2.5 mg of neostigmine and 1 mg of atro-
pine; patients were tracheally intubated and transferred to
the PACU.
Postoperative analgesia: After arrival at the PACU, pa-
tients were asked every 30 minutes whether they needed
analgesics until they were alert enough to use the patient-
controlled analgesia (PCA) pump [12]. When analgesics
were required, 0.02 mg/kg of IV morphine was adminis-
tered. The pump was set to deliver at 1 mg/h (background
infusion), after which a 1 mg bolus dose with a lockout
time of 10 minutes was given. In cases where the max-
imum permitted dose of morphine was reached and the
patient continued to report pain, a second opioid anal-
gesic, pethidine, was given. PCA with morphine was
started immediately after patients were able to control the
PCA pump in the PACU.
Evaluation of chronic postsurgical pain
The incidence of the postoperative residual pain in the
pelvis and at the scar area was evaluated in all 102 patients
three months after surgery (according to the International
Association for the Study of Pain chronic pain definition
[29]), by a research nurse via telephone interviews. The
following questions were asked to define CPP location and
duration as well as painkiller consumption, as described
elsewhere [30]: 1) Do you feel any pain at the scar area or
pelvis?; 2) What is the duration of the pain?; and 3) Do
you take any medication to alleviate the pain? If pain was
reported, the NRS (0-no pain, 10-worst pain) was used to
assess pain intensity. If patients reported an increase in
pain over the past month or change in pain sensation, they
were advised to contact the pain clinic. These patients
were evaluated at the pain clinic using the DN4 Question-
naire, a screening tool for neuropathic pain [31,32].
Genotyping
Whole blood samples were transported to the Depart-
ment of Gene Technology at the Tallinn University of
Technology, where genotyping analysis was performed
[12]. Lymphocytes were isolated from blood specimens
using Ficoll-Paque gradients, and genomic DNA was
isolated using the Puregene DNA Purification Kit
(Gentra Systems, Minneapolis, MN). Variants of the
OPRM1 gene were prepared by DNA sequence analysis
of polymerase chain reaction (PCR)-amplified DNA,
using primers located in flanking intron sequence.
OPRM1 exon 1 (from the genomic sequence accession
number NC000006 nucleotides 154402000–2800) was
amplified by PCR with primers F1: CAGAAGAGTG
CCCAGTGAAGA and R755: TACCTCCCCTCTTTCA
TCCTC and sequenced directly with the additional pri-
mer F177: CGCAGAGGAGAATGTCAGATG. COMT
exon 4 (from the genomic sequence accession number
NC000022, nucleotides 18331000–1400 SNP G>A,
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CTCATCACCATCGAGATCAAC and R301: CCTTTT
TCCAGGTCTGACAAC. Amplified DNA was cut with
the restriction enzyme Hin1 II. When Guanosine was
added after gel agarose (2%) electrophoresis, 87 and 29
base pair long fragments were created. Adenosine gave
rise to 69, 18, and 29 base pair long fragments. The
genotyping error rate was directly determined by re-
genotyping 25% of the samples randomly chosen for each
locus. The overall error rate was determined to be < 0.005.Statistical analysis
Numerical variables were summarized using the mean
and standard deviation, and categorical variables were
summarized as N and percentage (%). Patients’ demo-
graphics and baseline characteristics between CPP and
non-CPP patients were compared using t-test or Fisher’s
exact test.
Before genetic association analysis, Hardy–Weinberg
equilibrium (HWE) was first assessed via exact test and
confirmed for the OPRM1 and COMT SNPs. First, multiple
logistic regression analysis was used to test all patients for
association between CPP status and each SNP, adjusting for
age, sex, and baseline pain score. We evaluated additive,
dominant, and recessive genetic inheritance (i.e., gene-
dosage effect) models for each SNP in relationship to CPP
status, in which the genotypes were coded as (0, 1, 2),
(0, 1, 1), and (0, 0, 1) based on the numbers of variant
alleles. In other words, the homozygote of the wide-type
or major allele was always used as the referent category
for statistical comparison. Second, for the CPP patients,
the association of each SNP with the intensity of CPP
score (or duration of pain) was evaluated assuming three
gene-dosage effect models after adjusting for sex, age,
baseline pain score, and pain medication using the analysis
of covariance (ANCOVA) method. Similar analyses were
also performed for combined COMT/OPRM1 genotypes.
All statistical analyses were performed using the SAS
software, version 9.2 (SAS Institute, Cary, NC) and the
PLINK software [33]. A P-value of less than 0.05 was
considered to be statistically significant.Additional files
Additional file 1: Table S1. Pain scores and duration of pain in 35 CPP
patients stratified by gender.
Additional file 2: Table S2. Distribution of genotypes by gender for
COMT rs4680 and OPRM1 rs1799971.Abbreviations
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